{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:38:24Z","timestamp":1759412304798,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3590-y","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T07:23:51Z","timestamp":1545204231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Seroprevalence of measles vaccine antibody response in vertically HIV-infected children, in Morocco"],"prefix":"10.1186","volume":"18","author":[{"given":"Houda","family":"Haban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumia","family":"Benchekroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Sadeq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latifa","family":"Tajounte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hinda Jama","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelaziz","family":"Benjouad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Amzazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hicham","family":"Oumzil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3164-8689","authenticated-orcid":false,"given":"Elmir","family":"Elharti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,19]]},"reference":[{"key":"3590_CR1","first-page":"155","volume":"72","author":"B Burstrom","year":"1995","unstructured":"Burstrom B, Aaby P, Mutie DM. Measles in infants: a review of studies on incidence, vaccine efficacy and mortality in East Africa. East Afr Med J. 1995;72:155\u201361.","journal-title":"East Afr Med J"},{"key":"3590_CR2","first-page":"471","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","unstructured":"Centers for Disease Control and Prevention. Update: global measles control and mortality reduction worldwide, 1991\u20132001. MMWR Morb Mortal Wkly Rep. 2003;52:471\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3590_CR3","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/jamapediatrics.2016.1787","volume":"170","author":"JC Bester","year":"2016","unstructured":"Bester JC. Measles and measles vaccination: a review. JAMA Pediatr. 2016;170:1209\u201315.","journal-title":"JAMA Pediatr"},{"key":"3590_CR4","unstructured":"Masrecha BG,Dixon MG, Kriss JK, et al. Progress towards measles elimination, African region, WHO weekly epidemiological record. 2017;18(92):229-40."},{"key":"3590_CR5","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.15585\/mmwr.mm6544a6","volume":"65","author":"MK Patel","year":"2016","unstructured":"Patel MK, Gacic-Dobo M, Strebel PM, et al. Progress toward regional measles elimination - worldwide, 2000-2015. MMWR Morb Mortal Wkly Rep. 2016;65:1228\u201333.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3590_CR6","unstructured":"Nshimirimana D, Roungou JP. The effort to attain measles pre-elimination targets by 2012 and to eliminate measles in the African region by 2020. 2010. \n                    http:\/\/www.aho.afro.who.int\/fr\/ahm\/issue\/11\/reports\/effort-attain-measles-pre-elimination-targets-2012-and-elimniate-measles\n                    \n                  . Accessed 16 June 2017."},{"key":"3590_CR7","unstructured":"PAHO. WHO Region of the Americas is declared free of measles. \n                    http:\/\/www.paho.org\/hq\/index.php?option=com_content&view=article&id=12528%3Aregion-americas-declared-free-measles\n                    \n                  . Accessed 28 Aug 2017."},{"key":"3590_CR8","first-page":"511","volume":"63","author":"N Teleb","year":"2014","unstructured":"Teleb N, Lebo E, Ahmed H, et al. Progress toward measles elimination-eastern Mediterranean region, 2008-2012. MMWR Morb Mortal Wkly Rep. 2014;63:511\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3590_CR9","volume-title":"Report on the intercountry meeting on measles\/rubella control and elimination","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Report on the intercountry meeting on measles\/rubella control and elimination. 2014. \n                    http:\/\/applications.emro.who.int\/docs\/IC_Meet_Rep_2014_EN_15410.pdf?ua=1\n                    \n                  . Accessed 14 Jul 2017."},{"key":"3590_CR10","unstructured":"Minist\u00e8re de la sant\u00e9, Programme National d\u2019Immunisation. 2013. \n                    http:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=0ahUKEwim2tK00sLWAhWCahoKHcJABGMQFggqMAE&url=http%3A%2F%2Fwww.sante.gov.ma%2FDocuments%2FManuel_PNI_29Juin2013_VersionImprime_SIPAMA.pdf&usg=AFQjCNHYUhEueMiO0jtY6wDnoSklHQNPDw\n                    \n                  . Accessed 14 Aug 2017."},{"key":"3590_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12325-015-0188-2","volume":"32","author":"A Cheikh","year":"2015","unstructured":"Cheikh A, Ziani M, Cheikh Z, et al. Measles in Morocco: epidemiological profile and impact of vaccination strategy. Adv Ther. 2015;32:172\u201383.","journal-title":"Adv Ther"},{"key":"3590_CR12","first-page":"227","volume":"10","author":"T Benamar","year":"2014","unstructured":"Benamar T, Alla A, Cherkaoui I, et al. Progress towards measles elimination in Morocco. Eur Sci J. 2014;10:227\u201340.","journal-title":"Eur Sci J"},{"key":"3590_CR13","volume-title":"Programme National d\u2019Immunisation. Evolution et perspective","author":"K Lahlou","year":"2016","unstructured":"Lahlou K. Programme National d\u2019Immunisation. Evolution et perspective. 2016. \n                    http:\/\/docplayer.fr\/29890703-Programme-national-d-immunisation-evolution-et-perspectives-dr-k-lahlou-directeur-de-la-population-casablanca-janvier-2016.html\n                    \n                  . Accessed 14 Jun 2017."},{"key":"3590_CR14","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jama.1992.03480090085032","volume":"267","author":"LJ Kaplan","year":"1992","unstructured":"Kaplan LJ, Daum RS, Smaron M, et al. Severe measles in immunocompromised patients. JAMA. 1992;267:1237\u201341.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"3590_CR15","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1093\/infdis\/jir071","volume":"204","author":"P Scott","year":"2011","unstructured":"Scott P, Moss WJ, Gilani Z, et al. Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity. J Infect Dis. 2011;204(Suppl 1):S164\u201378.","journal-title":"J Infect Dis"},{"key":"3590_CR16","first-page":"314","volume":"99","author":"ML McMorrow","year":"2009","unstructured":"McMorrow ML, Gebremedhin G, van den Heever J, et al. Measles outbreak in South Africa, 2003-2005. South Afr Med J. 2009;99:314\u20139.","journal-title":"South Afr Med J"},{"key":"3590_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/tropej\/fmk002","volume":"52","author":"RW Setse","year":"2006","unstructured":"Setse RW, Cutts F, Monze M, et al. HIV-1 infection as a risk factor for incomplete childhood immunization in Zambia. J Trop Pediatr. 2006;52:324\u20138.","journal-title":"J Trop Pediatr"},{"key":"3590_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/1096-8652(200102)66:2<92::AID-AJH1023>3.0.CO;2-J","volume":"66","author":"MW Hilgartner","year":"2001","unstructured":"Hilgartner MW, Maeder MA, Mahoney EM, et al. Response to measles, mumps, and rubella revaccination among HIV-positive and. Am J Hematol. 2001;66:92\u20138.","journal-title":"Am J Hematol"},{"key":"3590_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/infdis\/165.2.262","volume":"165","author":"JE Embree","year":"1992","unstructured":"Embree JE, Datta P, Stackiw W, et al. Increased risk of early measles in infants of human immunodeficiency virus type. J Infect Dis. 1992;165:262\u20137.","journal-title":"J Infect Dis"},{"key":"3590_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1468-1293.2006.00409.x","volume":"7","author":"L Aurpibul","year":"2006","unstructured":"Aurpibul L, Puthanakit T, Siriaksorn S, et al. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy. HIV Med. 2006;7:467\u201370.","journal-title":"HIV Med"},{"key":"3590_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1468-1293.2011.00982.x","volume":"13","author":"EN Menson","year":"2012","unstructured":"Menson EN, Mellado MJ, Bamford A, et al. Guidance on vaccination of HIV-infected children in Europe. HIV Med. 2012;13:333\u20136 e1-14.","journal-title":"HIV Med"},{"key":"3590_CR22","first-page":"349","volume":"84","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. Measles vaccine WHO position paper. Wkly Epidemiol Rec. 2009;84:349\u201360.","journal-title":"Wkly Epidemiol Rec"},{"key":"3590_CR23","doi-asserted-by":"publisher","unstructured":"World Health Organization. Measles vaccines: WHO position paper. April 2017 - Recommendations. Vaccine. 2017. [cited 2017 Aug 23];[4p.]. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.066\n                    \n                  .","DOI":"10.1016\/j.vaccine.2017.07.066"},{"key":"3590_CR24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJM199003013220903","volume":"322","author":"LE Markowitz","year":"1990","unstructured":"Markowitz LE, Sepulveda J, Diaz-Ortega JL, et al. Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med. 1990;322:580\u20137.","journal-title":"N Engl J Med"},{"key":"3590_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijid.2016.07.012","volume":"50","author":"LA Al-Mekaini","year":"2016","unstructured":"Al-Mekaini LA, Kamal SM, Al-Jabri O, et al. Seroprevalence of vaccine-preventable diseases among young children in the United Arab Emirates. Int J Infect Dis. 2016;50:67\u201371.","journal-title":"Int J Infect Dis"},{"key":"3590_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4161\/hv.36162","volume":"11","author":"L Sticchi","year":"2015","unstructured":"Sticchi L, Bruzzone B, Caligiuri P, et al. Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients. Hum Vaccines Immunother. 2015;11:263\u20139.","journal-title":"Hum Vaccines Immunother"},{"issue":"Suppl 3","key":"3590_CR27","doi-asserted-by":"publisher","first-page":"C61","DOI":"10.1016\/j.vaccine.2012.02.040","volume":"30","author":"MJ Mphahlele","year":"2012","unstructured":"Mphahlele MJ, Mda S. Immunising the HIV-infected child: a view from sub-Saharan Africa. Vaccine. 2012;30(Suppl 3):C61\u20135.","journal-title":"Vaccine"},{"key":"3590_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/INF.0b013e3181903ed3","volume":"28","author":"C Farquhar","year":"2009","unstructured":"Farquhar C, Wamalwa D, Selig S, et al. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination. Pediatr Infect Dis J. 2009;28:295\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"3590_CR29","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/infdis\/jit404","volume":"208","author":"K Rainwater-Lovett","year":"2013","unstructured":"Rainwater-Lovett K, Nkamba HC, Mubiana-Mbewe M, et al. Changes in measles serostatus among HIV-infected Zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities. J Infect Dis. 2013;208:1747\u201355.","journal-title":"J Infect Dis"},{"key":"3590_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/INF.0000000000001422","volume":"36","author":"CG Sutcliffe","year":"2017","unstructured":"Sutcliffe CG, Searle K, Matakala HK, et al. Measles and rubella Seroprevalence among HIV-infected and uninfected Zambian youth. Pediatr Infect Dis J. 2017;36:301\u20136.","journal-title":"Pediatr Infect Dis J"},{"key":"3590_CR31","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1542\/peds.2005-2616","volume":"118","author":"V Bekker","year":"2006","unstructured":"Bekker V, Scherpbier H, Pajkrt D, et al. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics. 2006;118:e315\u201322.","journal-title":"Pediatrics"},{"key":"3590_CR32","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/INF.0000000000000332","volume":"33","author":"LP Newman","year":"2014","unstructured":"Newman LP, Njoroge A, Ben-Youssef L, et al. Measles seropositivity in HIV-infected Kenyan children on antiretroviral therapy. Pediatr Infect Dis J. 2014;33:843\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"3590_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/cei.12619","volume":"181","author":"MB Buechler","year":"2015","unstructured":"Buechler MB, Newman LP, Chohan BH, et al. T cell anergy and activation are associated with suboptimal humoral responses to measles revaccination in HIV-infected children on anti-retroviral therapy in Nairobi, Kenya. Clin Exp Immunol. 2015;181:451\u20136.","journal-title":"Clin Exp Immunol"},{"key":"3590_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/COH.0000000000000092","volume":"9","author":"S Moir","year":"2014","unstructured":"Moir S, Fauci AS. B-cell exhaustion in HIV infection: the role of immune activation. Curr Opin HIV AIDS. 2014;9:472\u20137.","journal-title":"Curr Opin HIV AIDS"},{"key":"3590_CR35","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.1016\/j.vaccine.2009.09.063","volume":"27","author":"PF Belaunzaran-Zamudio","year":"2009","unstructured":"Belaunzaran-Zamudio PF, Garcia-Leon ML, Wong-Chew RM, Villas\u00eds-Keever A, Cuellar-Rodriguez J, Mosqueda-Gomez JL, et al. Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. Vaccine. 2009;27:7059\u201364.","journal-title":"Vaccine"},{"key":"3590_CR36","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.4161\/hv.21827","volume":"8","author":"A Cagigi","year":"2012","unstructured":"Cagigi A, Cotugno N, Giaquinto C, et al. Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions. Hum Vaccines Immunother. 2012;8:1784\u201394.","journal-title":"Hum Vaccines Immunother"},{"key":"3590_CR37","doi-asserted-by":"publisher","first-page":"7939","DOI":"10.1073\/pnas.0901702106","volume":"106","author":"S Pensieroso","year":"2009","unstructured":"Pensieroso S, Cagigi A, Palma P, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci U S A. 2009;106:7939\u201344.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3590_CR38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/infdis\/jis386","volume":"206","author":"MJ Abzug","year":"2012","unstructured":"Abzug MJ, Qin M, Levin MJ, et al. Immunogenicity, immunologic memory, and safety following measles revaccination in. J Infect Dis. 2012;206:512\u201322.","journal-title":"J Infect Dis"},{"key":"3590_CR39","doi-asserted-by":"publisher","unstructured":"Newman LP, Njoroge A, Magaret A, et al. Sustained responses to measles revaccination at 24 months in HIV-infected children on antiretroviral therapy in Kenya. Pediatr Infect Dis J. 2017. \n                    https:\/\/doi.org\/10.1097\/INF.0000000000001572\n                    \n                  .","DOI":"10.1097\/INF.0000000000001572"},{"key":"3590_CR40","first-page":"205","volume":"92","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Measles vaccines: WHO position paper\u2013April 2017. Wkly Epidemiol Rec. 2017;92:205\u201327.","journal-title":"Wkly Epidemiol Rec"},{"key":"3590_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309\u201318.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3590-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3590-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3590-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T19:06:06Z","timestamp":1576695966000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3590-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3590"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3590-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"5 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prior to participation in this study, parents or guardians of children signed a written informed consent.The Ethic Committee of Biomedical Research, Medical School and Pharmacy, University Mohammed V<sup>th<\/sup>, Rabat, gave the approval for this study. Committees\u2019 reference: 1222\/2010.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"680"}}